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ABSTRACT
Background. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin re-
ceptor blockers (ARB) are themost commonly prescribed antihypertensivemedications
in higher-risk surgical patients. However, there is no clinical consensus on their use in
the perioperative period, in part, due to an inconsistent evidence-base. To help inform
the design of a large multi-centre randomized controlled trial (ISRCTN17251494), we
undertook a questionnaire-based survey exploring variability in ACEi/ARB prescribing
in perioperative practice.
Methods. The online survey included perioperative scenarios to examine how consis-
tent respondents were with their stated routine preoperative practice. Clinicians with
an academic interest in perioperative medicine were primarily targeted between July
and September 2017. STROBE guidelines for observational research and ANZCA Trials
Group Survey Reporting recommendations were adhered to.
Results. 194 responses were received, primarily from clinicians practicing in the UK.
A similar minority of respondents continue ACEi (n= 57; 30%) and ARBs (n= 62;
32%) throughout the perioperative period. However, timing of preoperative cessation
was highly variable, and rarely influenced by the pharmacokinetics of individual ACE-
i/ARBs. Respondents’ stated routine practice was frequently misaligned with their
management of common pre- and postoperative scenarios involving continuation or
restarting ACE-i/ARBs.
Discussion. This survey highlights many inconsistencies amongst clinicians’ practice
in perioperative ACE-i/ARB management. Studies designed to reveal an enhanced un-
derstanding of perioperative mechanisms at play, coupled with randomised controlled
trials, are required to rationally inform the clinical management of ACE-i/ARBs in
patients most at risk of postoperative morbidity.
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INTRODUCTION
Over 1.5 million high-risk patients undergo surgery in the UK every year (Abbott et
al., 2017a). Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor
blockers (ARB) are the most commonly prescribed antihypertensive medications in
high-risk surgical patients (Abbott et al., 2017b; Ackland et al., 2015; Pearse et al., 2014).
While the benefits of ACEi/ARBs in hypertension, ischaemic heart disease, heart failure,
diabetes mellitus and renal disease are well-recognised (SPRINT Research Group et al.,
2015; Heart Outcomes Prevention Evaluation Study Investigators et al, 2000; Yusuf et al.,
2003), continuation of their use throughout the entire perioperative period remains
controversial.
Directly conflicting data raise significant doubts about the perioperative management
of ACEi/ARBs in noncardiac surgery. Some, but not all, early-phase observational clinical
studies (Brabant et al., 1999; Schulte et al., 2011) report association between ACEi/ARBs
and perioperative hypotension, according to a variety of definitions (Abbott et al., 2017c;
Bijker et al., 2007; Vaquero Roncero et al., 2017). However, these data contrast with the
results of large clinical database studies using objective outcome measures, which provide
markedly divergent findings in noncardiac surgery. Both failure to restart ACEi/ARB
therapy after surgery (Lee, Takemoto & Wallace, 2015; Mudumbai et al., 2014), and not
stopping ACEi/ARBs before surgery (Roshanov et al., 2017), have been associated with
increased incidence of postoperative mortality in both noncardiac and cardiac surgery.
Conversely, the Cleveland Clinic Outcomes Research group found no association between
perioperative ACEi use and the incidence of postoperative complications or mortality in
>79,000 patients undergoing non-cardiac surgery (Turan et al., 2012). In keeping with
these conflicting data, three systematic reviews conclude that the evidence surrounding
perioperative ACEi/ARB use is characterised by retrospective, observational studies of low
methodological quality, high risk of bias and a lack of power to explore objective outcomes
(most notably, postoperative morbidity) (Hollmann, Fernandes & Biccard, 2018; Vaquero
Roncero et al., 2017; Zou et al., 2016). Moreover, the failure to take into account the variable
pharmacokinetic characteristics of ACEi/ARBs may be an additional confounder (Michel
et al., 2013).
To help inform the design and conduct of a randomised controlled trial now underway
(ISRCTN17251494), we undertook a survey to determine the current state of practice and
opinions regarding perioperative ACEi/ARB use in noncardiac surgery. Our data indicate
that there is widespread uncertainty regarding the perioperative use of ACEi/ARB. This
reinforces the need for a randomized controlled trial to inform clinical practice.
METHODS
Study design
We used the PICO framework to design this online survey of practice regarding the
perioperative use of ACEi/ARB, as detailed in Table 1. The study received research ethics
approval (QMREC1735;QueenMary, University of LondonEthics of ResearchCommittee)
and was conducted in accordance with the principles of the Declaration of Helsinki and the
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Table 1 PICOmodel to frame questions for survey.
Patient: Patients undergoing non-cardiac surgery, requiring ACE-inhibitor and/or
angiotensin receptor blocking therapy for cardiometabolic and/or renal disease.
Intervention: Withdrawal of ACE-inhibitor and/or angiotensin receptor blockade therapy.
Comparison: Continuation of ACE-inhibitor and/or angiotensin receptor blockade therapy.
Outcome: Identify perioperative practice under different common clinical scenarios.
Research Governance Framework. We adhered to STROBE guidelines for observational
research, although these do not include reporting characteristics that are specific for surveys
(Von Elm et al., 2007). In addition, we also used the ANZCATrials Group Survey Reporting
List (Appendix S1) to ensure transparency and reproducibility (Story et al., 2011).
Questionnaire design
The survey consisted of 11 questions designed to ascertain opinions regarding perioperative
ACEi/ARB use and illicit routine perioperative prescribing patterns. Questions were
structured using two complementary approaches (Appendix S2). Firstly, five questions had
a constructed response format, which were designed to directly address perioperative
prescribing patterns. Secondly, six questions were based on common perioperative
scenarios, which aimed to examine whether simple clinical guidelines for these drugs
are easily generalisable. This section entailed several common clinical challenges including
pre- and postoperative hypertension, early perioperative myocardial injury and relative
postoperative hypotension (see Appendix S2). The final three questions addressed
respondents, current grade and location of practice as well as their clinical background.
The survey was constructed by a writing group (KB, TA, GA) and was initially piloted
amongst anaesthetists at The Royal London Hospital, Barts Health NHS Trust. The survey
underwent external peer review and second-round piloting at the Health Services Research
Centre, Royal College of Anaesthetists, UK. The final version of the survey was approved
for clarity and feasibility by all authors.
Participants and survey administration
Participation in the survey was voluntary and responses were anonymised. Participants
were identified and invited via three routes: 33 attendees at the Perioperative Quality
Initiative (POQI) Consensus Conference on perioperative management of arterial blood
pressure (2017), 161 principal investigators from 120 UK centres that contributed
to the International Surgical Outcomes Study (ISOS; Appendix S3) and an open
invitation to members of the Royal College of Anaesthetists (issued on 26 June 2017;
https://www.rcoa.ac.uk/rcoa-presidents-news-june-2017). Detailed information on the
study was provided in a letter sent by e-mail explaining the goals and design of the study,
specifying confidentiality and the handling of data. Formal written consent was not required
before participation. However, consent was implied through participation. Participants
answered the questions via an online survey (SurveyMonkey). Two e-mail reminders were
sent to optimise the response rate.























Figure 1 Routine pre-operative practice for ACEi and ARB.
Full-size DOI: 10.7717/peerj.5061/fig-1
Statistical methods
Categorical data are presented as n (%), analyzed by Fishers exact test, and presented
as odds ratios (95% confidence intervals). All reported p values are two-sided, with
significance defined by p values≤0.05. Statistical analyses were performed using GraphPad
Prism software (La Jolla, CA, USA).
RESULTS
194 anonymised surveys were collected in total between 26 June 2017 and 31 September
2017, with a 64.4% response rate from 125/194 POQI/ISOS investigators (Fig. S1). 183
(96%) respondents practiced perioperative medicine within the United Kingdom and 163
(84.5%) were consultants in perioperative medicine/anaesthesia.
Planned preoperative prescription
A similar minority of respondents continue ACEi (n= 57; 30%) and ARBs (n= 62; 32%)
throughout the perioperative period. Amongst the 135 (70%) participants who routinely
stop ACEi prior to surgery, 97 (72%) routinely recommend ACEi/ARB cessation on the
day of surgery. Only three (2%) participants base ACEi/ARB cessation on the half-life of
the drug (Fig. 1).
Planned postoperative prescription
Correspondents reported that a variable time at which ACEi/ARBs were restarted after
surgery (Fig. 2). 76 (40%) and 78 (41%) respondents would restart ACEi or ARBs within
24 h of major surgery, respectively. The practice of routinely stopping ACEi/ARBs was
associated with >24 h delay in restarting ACEi/ARBs (odds ratio: 3.44 (95%CI [1.81–6.41]);
p< 0.001; Fig. 3).


















Timepoint for restarting drug (hours after surgery)
Figure 2 Routine post-operative practice for ACEi and ARB use.
Full-size DOI: 10.7717/peerj.5061/fig-2
Figure 3 Association between planned pre- and post-operative practice. Routinely stopping
ACEi/ARBs in the pre-operative setting was associated with a > 24 hr delay in restarting the drug
(odds ratio: 3.44 (95% CI [1.81–6.41]); p< 0.001).
Full-size DOI: 10.7717/peerj.5061/fig-3
Management of preoperative hypertension, on the day of surgery
(questions 6, 7, 8)
When faced with the scenario of an acutely hypertensive patient (mean arterial pressure
>160 mmHg) immediately before surgery, respondents did not appear to consider the
preoperative use of ACEi/ARB as an important influence on proceeding to surgery. For
patients normally on ACEi/ARB who had stopped the drug pre-operatively, there was
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Figure 4 Clinical scenarios: survey questions 6–9.
Full-size DOI: 10.7717/peerj.5061/fig-4
no association between respondents’ usual pre-operative practice (continuing versus
stopping ACEi/ARB) and decision to proceed to surgery on that day (OR:2.37 (95% CI
[0.85–6.2]); p= 0.10; question 7; Fig. 4). Untreated hypertension was more likely to trigger
postponement of surgery than hypertension in patients already prescribed ACEi/ARB
(OR:1.71 (95% CI [1.07–2.73]); p= 0.03; question 6; Fig. 4).
Management of postoperative blood pressure in the early
postoperative period (question 9)
169 (87%) respondents declined to restart ACEi/ARBs within 24 h in a stable, high-risk
patient on chronic ACEi/ARBs if their systolic blood pressure was 90–100 mmHg. For
respondents who advocated continuing ACEi/ARBs throughout the perioperative period,
faced with this scenario only 11 (20%) would continue ACEi/ARBs. However, these
respondents who advocated continuing ACEi/ARBs were three times more likely to restart
the drug (OR:3.17 (95% CI [1.26–8.24]); p< 0.05; Fig. 4).
Management of suspected postoperative myocardial injury
(questions 10, 11)
Postoperative hypertension (systolic arterial pressure >170 mmHg) associated with
clinically asymptomatic rise in plasma high-sensitivity troponin on postoperative day
one prompted 110 (57%) of respondents to restart ACEi/ARB in patients established on
this therapy (Fig. 5). By contrast, less than 6% commenced ACEi/ARB in patients with
a similar postoperative picture who were not already receiving ACEi/ARBs, deferring to
specialist advice.
Walker et al. (2018), PeerJ, DOI 10.7717/peerj.5061 6/12
Figure 5 Impact of postoperative myocardial injury on ACEi/ARB use. An asymptomatic rise in tro-
ponin post-operatively would prompt 110 (57%) to restart ACEi/ARBs in those already established on this
therapy. In those patients not already receiving ACEi/ARBs, a similar asymptomatic troponin rise prompts
only 6% to commence the drug deferring to specialist advice.
Full-size DOI: 10.7717/peerj.5061/fig-5
DISCUSSION
The principal finding of this study is apparent widespread uncertainty surrounding the
perioperative management of ACEi/ARB, even amongst experienced clinicians with an
academic interest in perioperative blood pressure control and postoperative outcomes.
This may be partly due to the different indications for ACEi/ARB therapy. This mirrors
the conclusions of three independent systematic reviews that were unable to provide any
recommendation on perioperative management of ACEi/ARB, chiefly due to poor study
design and the lack of objective outcomes (Hollmann, Fernandes & Biccard, 2018; Vaquero
Roncero et al., 2017; Zou et al., 2016).
Surgical patients with cardiac failure are at high-risk of postoperative morbidity and
mortality (Abbott et al., 2016; Abbott et al., 2017c; Abbott et al., 2017d; Hammill et al., 2008;
Hernandez et al., 2004). Moreover, many surgical patients are deconditioned and share
strikingly similar cardiopulmonary physiology with cardiac failure patients (Abbott et al.,
2017b). As revealed by cardiopulmonary exercise testing, many of these surgical patients
have impaired left ventricular function- even though they have no formal diagnosis of
cardiac failure. Registry data for hospitalized, cardiac failure patients show that 30-day
mortality was substantially higher in those in whom ACEi/ARBs were discontinued
(adjusted hazard ratio [HRadj] 1.92; 95% CI [1.32–2.81]; P < 0.001), with the readmission
rate post-discharge lowest among patients continued or started on therapy (Gilstrap et al.,
2017). These marked outcome differences persisted after discharge, with higher one-year
mortality (41.6%) associated with discontinuation of ACEi/ARBs (HRadj 1.35; 95% CI
[1.13–1.61]; P < 0.001).
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Our survey also highlighted that individualisation of preoperative ACEi/ARB
management is seldom considered by clinicians. ARBs have very different terminal half-
lives, receptor binding kinetics, active metabolic components, highly variable volumes of
distribution and some exhibit insurmountable antagonism, compared to ACEi (Michel et
al., 2013). Thus, a one-size-fits-all approach for perioperative ACEi/ARB management is
illogical. However, studies in which perioperative ACEi/ARB therapy was stopped have
failed to consider the type of ACEI/ARB, patient indication for therapy or the time point
at which ACEi/ARB therapy was restarted.
Strengths of this survey, which is the largest undertaken thus far, include deliberately
targeting experienced clinicians (ISOS/POQI investigators) with an academic interest in
perioperative blood pressure control and postoperative outcomes. A further strength was
that, regardless of clinical/academic background, we probed the internal consistency of
each respondents, pre- and postoperative practice by further exploring specific scenarios.
This approach frequently revealed a disconnect between respondents, stated routine
practice and their answers to common postoperative scenarios. The survey is limited by a
relatively small sample that may not be representative of global practice, which is heavily
geographically biased towards the UK. The survey would be strengthened by corroborative
clinical data to assess whether respondents managed patients in a real world setting in
a similar manner to that reported in the survey. In accordance with ethical committee
requirements for survey responses to be completely anonymised, we cannot verify the exact
origin of correspondents. It is likely that more detailed scenarios including renal function
may have revealed more nuanced responses.
In conclusion, this survey suggests that the clinical management of ACEi/ARB therapy
is highly variable, and often internally inconsistent. This survey, and systematic reviews,
highlight the need for a mechanistic randomized controlled trial, using blinded outcomes
in patients most at risk of postoperative morbidity.
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